Concepedia

Deepthi Bhupathi

DB

Statistics

Publications

8

Citations

374

H-Index

8

Active since

2011

Affiliations

Threshold Pharmaceuticals (United States)(Current)

Deepthi Bhupathi is an author at Threshold Pharmaceuticals (United States) specializing in cancer pharmacology, medicine, and pharmacology.

Publications per year

2011–2023

8

Publications

8

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

Fanying Meng, James Evans, Deepthi Bhupathi et al. · Molecular Cancer Therapeutics · 2011 · 206 citations

, , +17

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia et al. · Cancer Biology & Therapy · 2015 · 51 citations · Full text

, , +17

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

Jessica D. Sun, Dharmendra Ahluwalia, Qian Liu et al. · PubMed · 2015 · 27 citations

, , +15

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

Fanying Meng, Deepthi Bhupathi, Jessica D. Sun et al. · BMC Cancer · 2015 · 24 citations · Full text

, , +17

14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment

Xiaohong Cai, Fanying Meng, Jessica D. Sun et al. · Journal of Medicinal Chemistry · 2011 · 21 citations

, , +11

1–5 of 8